Side-by-side comparison of AI visibility scores, market position, and capabilities
Nasdaq-listed (PRME). $191M cash runway into 2027. IND for Wilson's Disease H1 2026. AATD IND mid-2026. $3.5B+ BMS collaboration. CGD Phase 1 showing rapid function restoration after single infusion.
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable of making all 12 possible base-pair changes, small insertions, and deletions in DNA without double-strand breaks. The company has $191 million in cash runway into 2027, INDs planned for Wilson's Disease and Alpha-1 antitrypsin deficiency (AATD) in 2026, and a $55 million upfront collaboration with Bristol Myers Squibb worth up to $3.5 billion in milestones.
FY2025 (ended Mar 31, 2025): JPY 21.6887T (+6.2%) | Operating Profit: JPY 1.2134T (-12.2%) | FY2024: JPY 20.4286T (+20.8%) | Q3 FY2024 (9 months): Op Profit JPY 1.1399T, margin 7.0% | Auto sales down 297k (Asia impact) | FY2026 guidance: Net profit JPY 250B (-70.1%), Revenue JPY 20.3T (-6.4%)
Honda Motor Co., Ltd. is a Japanese multinational mobility conglomerate founded in 1948 by Soichiro Honda and Takeo Fujisawa in Hamamatsu, Japan. Starting as a motorcycle manufacturer, Honda expanded into automobiles, power equipment, marine engines, and aerospace, becoming one of the largest and most diversified mobility companies in the world. With over 90 million vehicles sold globally and a reputation built on engineering reliability, fuel efficiency, and innovation, Honda operates manufacturing facilities across more than 30 countries on six continents.\n\nHonda's automotive lineup ranges from mass-market sedans and SUVs — including the best-selling Civic and CR-V — to trucks, minivans, and the premium Acura brand. The company is executing a major pivot to electrification through the Honda 0 Series, a new EV architecture designed from the ground up for battery-electric vehicles launching in 2026. Honda's partnership with General Motors on battery technology, combined with its investment in solid-state battery development, reflects a multi-path electrification strategy designed to hedge technology risk while building scale.\n\nHonda reported FY2025 revenue of JPY 21.7 trillion, a 6.2% year-over-year increase, driven by strong North American demand and favorable currency tailwinds. The company faces intensifying competition from Chinese EV manufacturers in Asia and is exploring a potential merger with Nissan as part of broader Japanese automotive consolidation. Honda's engineering culture, global manufacturing scale, and brand credibility in reliability position it as a resilient and well-capitalized incumbent navigating the EV transition.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.